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Condensation: Parous women with previous normal pregnancies have the most 
favorable cardiac adaptation compared to nulliparous and to those with previous 
complicated pregnancies. 
 
Short title: Effect of parity on maternal cardiac adaptation. 
 
AJOG at a glance:  
 
A. The aim of this study was to compare maternal hemodynamics between 
nulliparous and parous women with and without previous preeclampsia or 
small for gestational age.  
 
B. Parous women without history of preeclampsia or birth of small for gestational 
age neonates have the most ideal hemodynamic profile during pregnancy with 
greatest cardiac output and lowest peripheral vascular resistance; nulliparous 
women demonstrate a similar trend over gestation but with lower cardiac 
output and higher peripheral vascular resistance. Parous women with history 
of preeclampsia or small for gestational age have decreasing cardiac output 
and increasing peripheral vascular resistance from mid-gestation. 
 
C. There are parity-specific differences in maternal hemodynamic adaptation to 
pregnancy. 
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Abstract  
Background: Parous women have a lower risk for pregnancy complications, such as 
preeclampsia (PE) or delivery of small for gestational age (SGA) neonates. However, 
parous women are a heterogeneous group of patients as they contain a low-risk 
cohort with previously uncomplicated pregnancies and a high-risk cohort with 
previous pregnancies complicated by PE and / or SGA. Previous studies examining 
the effect of parity on maternal hemodynamics, including cardiac output (CO) and 
peripheral vascular resistance (PVR), did not distinguish between parous women 
with and without a history of PE or SGA and reported contradictory results.  
Objectives: To compare maternal hemodynamics, in nulliparous women and in 
parous women with and without previous PE and / or SGA.  
Study design: This was a prospective, longitudinal study of maternal hemodynamics, 
assessed by a bioreactance method, measured at 11+0-13+6, 19+0-24+0, 30+0-34+0 
and 35+0-37+0 weeks’ gestation in three groups of women. Group 1 was composed of 
parous women without history of PE and / or SGA (n=632), Group 2 was of 
nulliparous women (n=829) and Group 3 was composed of parous women with 
history of PE and / or SGA (n=113). Multilevel linear mixed-effects model was 
performed to compare the repeated measures of hemodynamic variables controlling 
for maternal characteristics, medical history, and development of PE or SGA in the 
current pregnancy.  
Results: In groups 1 and 2, CO increased with gestational age to a peak at 32 weeks 
and PVR showed a reversed pattern with its nadir at 32 weeks; in group 1, compared 
to group 2, there was better cardiac adaptation, reflected in higher CO and lower 
PVR. In group 3 there was a hyperdynamic profile of higher CO and lower PVR at 
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first trimester followed by an earlier sharp decline of CO and increase of PVR from 
mid-gestation. The incidence of PE and SGA was highest in group 3 and lowest in 
group1. 
Conclusion: There are parity-specific differences in maternal cardiac adaptation in 
pregnancy.  
 
KEYWORDS: pregnancy, hemodynamics, cardiac output; peripheral vascular 
resistance, parous, nulliparous, parity, preeclampsia, fetal growth restriction, small 
for gestational age, bioreactance, placental insufficiency.  
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Introduction 
Incidence and severity of pregnancy complications, such as preeclampsia (PE) and 
birth of small for gestational age (SGA) neonates, are significantly higher in 
nulliparous, compared to parous women.1-4 However, parous women are a 
heterogeneous group of patients as they contain a low-risk cohort with previously 
uncomplicated pregnancies and a high-risk cohort with previous pregnancies 
complicated by PE and / or SGA. The latter represents a group of women at high-risk 
not only of pregnancy complications but also of cardiovascular morbidity and 
mortality in the decades after pregnancy.5-12 
Contrary to maternal cardiovascular adaptation in normal pregnancy which is 
characterized by a drop in peripheral vascular resistance (PVR) and increase in 
cardiac output (CO) which peaks at mid-gestation,13-15 in pregnancies complicated 
by PE and / or SGA, distinct hemodynamic profiles have been described.16-22 
Women destined to develop PE after 36 weeks’ gestation show a hyperdynamic 
state from the first trimester of pregnancy, with high CO and low PVR.23,24 This is 
maintained throughout the preclinical phase of the disease. Furthermore, a 
‘hemodynamic crossover’ with markedly reduced CO and significant vasoconstriction 
during the clinical disease was observed. 23 On the other hand, pregnancies 
complicated by SGA, with or without hypertension, have consistently low CO and 
high PVR throughout gestation.16-20,22,25,26 Previous studies comparing maternal 
cardiovascular adaptation between nulliparous and parous women have shown 
inconsistent results with some studies showing better27-29 and others reporting worse 
hemodynamic profiles in parous compared to nulliparous women.30 None of the 
above-mentioned studies stratified the parous women according to whether their 
previous pregnancies were complicated by PE and / or SGA. 
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We hypothesised that parous women without previous PE and / or SGA would 
have the best hemodynamic profile and pregnancy outcomes compared to 
nulliparous and parous women with previous PE or SGA. The objective of this study 
was to compare maternal hemodynamics between these three groups of pregnant 
women. 
Methods 
Study population 
This was a prospective, longitudinal study assessing maternal hemodynamics in 
women with singleton pregnancies attending routine pregnancy care at 11+0 to 13+6 
week’s gestation, conducted between November 2015 and May 2016 in six maternity 
hospitals in the UK. This is a sub-study of the Aspirin for Evidence-Based 
Preeclampsia Prevention (ASPRE) study; this multicentre study involved first-
trimester screening for PE by maternal factors and biomarkers,31 and those identified 
by screening to be at high-risk of PE were invited to participate in a trial of aspirin 
versus placebo.32 In our study women undergoing screening were approached to 
participate in the hemodynamics study irrespective of their screening status and 
therefore they represent an unbiased sample of a general obstetric population, 
where screen positive and negative women are randomly distributed within the 
subgroups of this study. Ethical approval was granted by the NHS Research Ethics 
Committee (REC reference: 13/LO/1479). The funding source had no role in the 
conduct of the research and preparation of the article. 
In our study, we recorded maternal demographic characteristics and medical 
history and performed hemodynamic studies at 11+0 to 13+6, 19+0 to 24+0, 30+0 to 34+0 
and 35+0 to 37+0 weeks’ gestation.  
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Maternal factors 
Maternal factors recorded included age, height, weight at each visit, racial origin 
(White, Black, South Asian, East Asian and mixed), method of conception 
(spontaneous or use of assisted reproductive technologies), cigarette smoking 
during pregnancy, medical history, medications, parity and obstetric history 
(nulliparous, parous with and without previous PE and / or SGA).   
Maternal hemodynamics 
A non-invasive, bioreactance method (NICOM, Cheetah Medical Ltd, Maidenhead, 
Berkshire, UK) validated both in pregnant and non-pregnant populations33-35 was 
used to assess maternal hemodynamics. Bioreactance uses the relative phase shifts 
occurring when an alternating electrical current traverse the thoracic cavity to 
calculate stroke volume (SV). Four dual-surface electrodes were applied across the 
maternal back and after 15 minutes of rest, cardiac variables [CO, SV, heart rate 
(HR), PVR and mean arterial pressure (MAP)] were recorded in a sitting position for 
10 minutes at 30-second intervals (20 cycles). The averages of the final 10 cycles of 
hemodynamic recordings were included in the analysis.  
Definitions 
We classified the study population into three groups: group 1, parous without history 
of PE or SGA; group 2, nulliparous and group 3, parous with history of PE or SGA. 
The definitions of non-proteinuric gestational hypertension (GH) and PE were those 
of the International Society for the Study of Hypertension in Pregnancy.36 Birthweight 
percentile for gestational age was derived from the Fetal Medicine Foundation 
reference range.37 SGA was defined as birthweight < 5th percentile for gestational 
age. Neonatal morbidity was defined by the presence of any one of respiratory 
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distress syndrome (requiring administration of surfactant and ventilation), need for 
ventilation (need of continuous positive airway pressure or intubation), neonatal 
sepsis (confirmed bacteremia in cultures), necrotizing enterocolitis requiring surgical 
intervention or neonatal hypoglycemia (blood glucose <46.8 mg/dL). 
Inclusion and exclusion criteria 
The inclusion criteria were singleton pregnancies resulting in the birth of 
morphologically normal livebirths or stillbirths at or after 24 weeks’ gestation and 
attendance for hemodynamic studies for at least three of the four visits. Exclusion 
criteria were maternal age <18 years, pre-existing maternal cardiac conditions, fetal 
abnormalities, incomplete follow-up and termination of pregnancy or miscarriage. 
Statistical analysis 
Maternal demographics, medical history, medication use and pregnancy outcomes 
between the three groups were compared using the chi-square test or Fisher’s exact 
test for categorical variables. The Kolmogorov – Smirnov test was used to assess 
the normality of the distribution of the numerical data. For the comparison of 
continuous data, the Kruskal-Wallis or the one-way ANOVA tests with post hoc 
analysis were used for not-normally and normally distributed data, respectively. Data 
are presented as median (interquartile range) and mean (standard deviation) or for 
not-normally and normally distributed continuous variables and as n (%) for 
categorical variables. The distribution of maternal weight, CO, SV, MAP and PVR 
were made Gaussian after log10 transformation. For the repeated measures analysis 
of the maternal hemodynamic variables, controlling for demographic characteristics, 
past medical history, medication use, pregnancy outcomes and time (the four visits), 
a multilevel linear mixed-effects model was performed. The fixed-effect component 
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included time (the four visits), study group, maternal age, log10 weight, height, race 
White, Black, South and East Asian and Mixed), conception, smoking, family history 
of PE, medical co-morbidities including chronic hypertension, autoimmune disease, 
asthma, diabetes mellitus type I and type II, medication use (labetalol, nifedipine or 
methyldopa, prednisolone), development of PE and SGA and first-order interaction 
between time and parity group. The likelihood radio (LR) test was used to define the 
best multilevel model (including only the random slope for time or random intercept 
versus including both the random intercept and slope) and to compare it with the 
base-model (with no random effects). The estimated marginal means of each 
hemodynamic variable at each race/time combination are presented.  
The software program IBM SPSS Statistics 23 (SPSS Inc., Chicago, IL, USA) 
was used for the statistical analysis (IBM Corp, Released 2015, IBM SPSS Statistics 
for Windows, Version 23.0, Armonk, NY: IBM Corp).  
Results 
Study population 
The study population of 1574 women included 632 in group 1, 829 in group 2, and 
113 in group 3. The maternal characteristics and pregnancy outcomes for the three 
groups at the screening visit are shown and compared in Table 1. In group 1, 
compared to group 2, maternal age and weight were higher, there was a higher 
incidence of women of Black racial origin, smoking, spontaneous conception and a 
lower incidence of PE and need for labetalol. Groups 1 and 2, compared to group 3, 
were taller and less likely to be smokers, to have a family history of PE and more 
likely to be of white race. Furthermore, groups 1 and 2 compared to 3, had less 
prevalence of medical co-morbidities, such as chronic hypertension and pre-existing 
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diabetes, less prevalence of PE and preterm PE and of delivery of neonate with 
birthweight below the 5th percentile and less need for treatment with nifedipine or 
methyldopa.  
Group 3 delivered the smallest infants compared to group 1 and 2. Women in 
group 2, compared to 1, had higher rate of neonatal morbidity.  
Multilevel linear mixed-effects models  
The fixed effects of the multilevel models are shown in Tables 2 and S1 and S2 and 
in Figures1 and 2.  
Maternal demographic characteristics medical history  
Increasing maternal age was associated with a decrease in Log10 CO, Log10 SV, HR 
and higher Log10 MAP. Increasing maternal height was associated with higher Log10 
CO, Log10 SV and lower HR and Log10 PVR. Maternal Log10 Weight was associated 
with higher Log10 CO, Log10 SV, HR and Log10 MAP. Compared to White race, Black, 
South, East Asian race were associated with lower Log10 CO, Log10 SV, Log10 MAP 
and greater Log10 PVR in Asians and HR in Black.  
Maternal chronic hypertension, use of labetalol, nifedipine or methyldopa were 
associated with higher Log10 MAP and Log10 PVR. Use of prednisolone was 
associated with higher Log10SV. Autoimmune disease was associated with lower 
Log10 CO and higher Log10 PVR and Log10 MAP. The development of PE was 
associated with lower HR and higher Log10 MAP. The delivery of SGA neonates was 
associated with lower HR and higher Log10 MAP. 
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There was no significant contribution in any of the models from spontaneous 
conception, family history of PE and diabetes mellitus Type I or II. There was 
significant interaction between parity groups and time for all the cardiac variables. 
Changes with time after controlling for maternal characteristics and outcome  
Log10 CO in both groups 1 and 2 increased during the first three visits and declined 
thereafter, with group 1 demonstrating greater Log10 CO throughout gestation (Figure 
1, Table 2, Supplementary Table 3). Log10 PVR (Figure 1, Table 2, Supplementary 
Table 3) and Log10 MAP (Figure 2, Table 2, Supplementary Table 3) demonstrated in 
both groups 1 and 2 a similar decline with gestation, with group 1 having lower 
values at all time points. Log10 SV in both groups 1 and 2 increased from the first to 
second visit, after which in the former it plateaued from the second to third visit and 
declined after that, whilst in the latter group it demonstrated a linear decrease from 
the second visit onwards (Figure 2, Table 2, Supplementary Table 3). HR in both 
groups 1 and 2, demonstrated a similar increase with gestation during the first three 
visits but contrary to group 1 which demonstrated a further small increase, HR of 
group 2 declined in the fourth visit (Figure 2, Table 2, Supplementary Table 3). 
In group 3, Log10 CO demonstrated a sharp decline and Log10 PVR showed a 
linear increase after the second visit. (Figure 1, Table 2, Supplementary Table 3) At 
the first and second visit, compared to group 1, Log10 CO was at higher level whilst 
Log10 PVR was lower. However, in the subsequent visits, group 3 demonstrated 
lower Log10 CO (Figure 1, Table 2, Supplementary Table 3) and higher Log10 PVR 
(Figure 1, Table 2, Supplementary Table 3) when compared to group 1. Log10 SV in 
groups 1 and 3 showed an opposing trend with the latter group starting at a higher 
point in the first visit, followed by a small and then a sharp decline from the second 
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visit onwards. (Figure 2, Table 2, Supplementary Table 3). On the contrary, Log10 SV 
in group 1 showed an increase from the first to third visit and a decline at the fourth 
visit only. HR in groups 1 and 3 shared similar incremental trends until the third visit, 
with group 3 being significantly higher than group 1 in the second visit (Figure 2, 
Table 2, Supplementary Table 3). Log10 MAP in both groups 1 and 3 showed similar 
linear decrease from first to third visit, followed by an increase towards the fourth 
visit, with group 3 having a persistently higher Log10 MAP than group 1 throughout 
gestation (Figure 2, Table 2, Supplementary Table 3).  
Comment 
Main findings of the study 
The results of this study have demonstrated that the hemodynamic profile in the 
current pregnancy is different in parous women without previous history of PE and / 
or SGA compared to nulliparous women and parous women with previous history of 
PE and / or SGA. The most favorable profile with increase in CO and decrease in 
PVR with advancing gestation was observed in parous women without previous PE 
and / or SGA; the increase in CO was associated with an increase in both SV and 
HR. In nullipara there was also an increase in CO and decrease in PVR but the 
magnitude of the changes was less; in these women HR was consistently lower and 
SV declined after the second visit. The most unfavorable hemodynamic profile was 
observed in parous women with previous PE and / or SGA where in the first half of 
pregnancy there was a high CO and low PVR but subsequently there was an abrupt 
decline in CO and increase in PVR.  
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The incidence of PE and SGA in the current pregnancy was highest in parous 
women with previous PE and / or SGA and lowest in parous women without previous 
PE and / or SGA.  
Interpretation of findings 
Maternal cardiovascular adaptation in normal pregnancy involves a decline in PVR 
that triggers a series of compensatory mechanisms, including an increase in 
maternal HR 13,15,38 and in SV39 leading to a 40% increase in CO that peaks around 
32 weeks’ gestation.14 Women who fail to achieve these adaptational changes have 
been shown to have higher rates of PE and or SGA40-42 and higher risk for 
cardiovascular disease.5-12  
Group 1 represents a subset of women who have successfully completed 
previous pregnancies with good outcomes and exhibit an optimal cardiovascular 
adaptation in the current pregnancy. There are two possible explanations for the 
optimal performance of this group. First, they have an inherent low risk for 
cardiovascular disease and adapt well to the cardiovascular stress of consecutive 
pregnancies. Second, their good response in their index pregnancy is the 
consequence of cardiac remodelling from their previous healthy pregnancy.43-45 
There is evidence that healthy pregnancy related cardiac remodelling persists for 
several years.46,47,48 Such persistent remodelling has also been reported in 
individuals undertaking temporary  endurance training.49,50,51  
Group 3 represents the cohort with the least favourable adaptive response to 
pregnancy. These women have failed the ‘cardiovascular screening test’ in their 
previous pregnancies and may have an underlying cardiovascular deficit, causing a 
failure in adaptation in situations of circulatory stress. Furthermore, previous 
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pregnancies complicated by PE and / or SGA may have inflicted additional insults to 
their pre-existing vulnerable cardiac function41,52 persisting after pregnancy and 
increasing their susceptibility to cardiovascular decompensation.9,53,54 Post-delivery, 
more than half of women with previous preterm PE have asymptomatic stage B heart 
failure and 40% develop essential hypertension within 2 years of delivery.46 
Therefore, when the heart of these women is at the edge of its reserve, any 
additional stress by yet another pregnancy would deplete its coping capabilities and 
result in maladaptation.  
It is noteworthy that women in group 3 began with a hyperdynamic output 
state with significantly higher CO and lower PVR compared to groups 1 and 2. A 
similar pattern has been described in non-pregnant populations in the pre-
hypertension state,55 particularly in obesity-induced hypertension which is more 
commonly observed in individuals younger than 60 years of age.56 In our cohort, the 
proportion of women who booked with severe obesity (BMI above 35 kg/m2) in group 
3 was two and three times more when compared to group 1 and 2. It has been 
reported that overactivity of the renin-angiotensin-aldosterone system (RAAS) is the 
main pathophysiology of obesity-induced hypertension,57 which explains the highest 
starting SV and CO observed in group 3. Initially, the overtly high CO causes a 
compensatory vasodilatation to maintain near-normal MAP, but the excessively 
dilated terminal arterioles would expose the endothelium to high shear stress, 
exhausting the vasodilatory rescue functions and resulting in damaged 
endothelium.58 The endothelial damage results in loss of plasma volume to the 
interstitial space and a gradual cross-over to a low-cardiac output and 
vasoconstricted state.23   
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Group 2 is a mixed cohort containing women that at the end of their 
pregnancies will be classified either in group 1 or 3. Therefore, their hemodynamic 
profile reflects the combination of good and bad cardiovascular reserve in this 
unscreened cohort for cardiovascular risk. 
Comparison with finding in previous studies 
Previous studies comparing hemodynamic profile and pregnancy between parous 
and nulliparous women did not stratify parous women according to the outcomes of 
their previous pregnancies. Our findings in parous women without previous PE and / 
or SGA by comparison to nulliparous women are consistent with the results of 
previous studies which reported that in parous, compared to nulliparous women, 
maternal plasma volume increase is steeper and more prolonged during 
pregnancy,59,60 blood pressure is lower61,61-64 and the incidence of SGA and PE is 
lower.3,4 In a previous study of women with normal pregnancy outcome we found 
that during the first-trimester CO, HR and SV were higher in parous than nulliparous 
women.27 Several small studies, comprising of 19-50 patients, reported that the 
hemodynamic profile of parous compared to nulliparous women was better or 
worse.28-30 
Strengths and limitations of the study 
Strengths of this study include first, the large sample size, second, the longitudinal 
assessment throughout pregnancy, and third, controlling in the mixed models for all 
those variables that may influence the hemodynamic variables, such as maternal 
demographic characteristics, medical history and PE or SGA in the current 
pregnancy.  
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When planning studies assessing maternal hemodynamics one needs to 
consider a plethora of variables that affect cardiac function. For example, gestational 
age, maternal height and weight, medical comorbidities (such as chronic 
hypertension, diabetes, asthma, autoimmune diseases, renal disease), medication 
(such as  steroids, antihypertensives, metformin, beta-mimetics) and pregnancy 
outcomes (PE, FGR) influence or are associated with maternal cardiac function 
variables. One option is to remove some of the above confounders; however, this 
would result in first,  removal of a large number of patients to the degree that the final 
sample is not representative of the initial population, second, removal of one 
parameter may influence interactions with other variables in the statistical model and 
third, removal of one specific parameter is arbitrary and not based on any logical 
process of preference against other parameters. For example, would chronic 
hypertension have more of an impact compared to an asthmatic patient who is 
receiving steroids and beta-mimetics? The second option is to allow all the 
population to be examined, controlling for the parameters that may influence the 
dependent variable. We have chosen the second approach as it is a more realistic 
representation of the overall population and it allows interactions to be highlighted.  
A limitation of this study is that we did not examine the effect of grand 
multiparity, as it has been associated with worse cardiovascular65 and pregnancy 
outcomes.2,66 This is because we only had 27 grand multipara, and hence not 
adequate power for such comparisons. However, it is likely that any possible effect in 
our models is controlled by correction for maternal age as women with high parity 
and long pregnancy interval also tend to be older.  Another limitation is that when 
reporting previous pregnancy outcome, we did not examine different subgroups 
according to the severity of PE and FGR and the gestational age at onset of these 
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conditions. However, such an attempt would necessitate the study of a much higher 
number of patients. 
Conclusion 
Our study has shown that the hemodynamic profile during pregnancy in parous 
women is different depending on the outcome of previous pregnancies. 
Consequently, studies investigating the relationship between hemodynamic profile 
and pregnancy outcome should stratify women according to the outcome of previous 
pregnancies.
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Table 1. Demographic characteristics and pregnancy outcome in the study population. 
 Parous no 
previous PE/SGA 
n=632 
Nulliparous 
n=829 
Parous previous 
PE/SGA 
n=113 
p-value 
Age in years, mean (SD) 32.0 (4.9) *** 30.3 (5.5)  31.6 (5.8) ‡‡‡ <0.0001 
Weight at booking in kg, median 
(IQR) 
70.0  
(61.5 to 82.0) ** 
67.3  
(59.3 to 79.0)  
69.0  
(59.3 to 86.4) ‡‡ 
0.006 
BMI at booking>35, n (%) 61 (9.7) ** 56 (6.8) +++ 22 (19.5) ‡‡ <0.0001 
Height in cm, mean (SD) 165.0 (6.4)  164.8 (6.6) ++ 162.4 (6.8) ‡‡ 0.001 
Smoking, n (%) 45 (7.1) ** 32 (3.9) + 15 (13.3) ‡‡‡ <0.0001 
Family history of PE, n (%) 29 (4.6) 56 (6.8) ++ 14 (12.4) ‡ 0.005 
Spontaneous conception, n (%) 625 (98.9) *** 791 (95.4) 112 (99.1) <0.0001 
Ethnicity     
- White, n (%) 456 (72.2) * 642 (77.4) ++ 67 (59.3) ‡‡‡ 0.000 
- Black, n (%) 110 (17.4) * 109 (13.1)  28 (24.8) ‡‡ 0.002 
- South Asian, n (%) 31 (4.9) 41 (4.9) 9 (8.0) 0.371 
- East Asian, n (%) 16 (2.5) 18 (2.2) 1 (0.9) 0.544 
- Mixed, n (%) 19 (3.0) 19 (2.3) + 8 (7.0) ‡‡ 0.018 
Chronic hypertension, n (%) 13 (2.1) 10 (1.2) ++ 9 (8.0) ‡‡‡ <0.0001 
Asthma, n (%) 6 (0.9) 15 (1.8) + 4 (3.5)  0.097 
Pre-existing diabetes, n (%) 4 (0.6) 2 (0.2) + 3 (2.7) ‡‡ 0.006 
Autoimmune, n (%) 1 (0.2) 6 (0.7) 0 (0.0) 0.209 
Labetalol, n (%) 22 (3.5) * 51 (6.2) ++ 12 (10.6)  0.003 
Nifedipine or methyldopa, n (%) 4 (0.6) 13 (1.6) +++ 7 (6.2) ‡‡ <0.0001 
Prednisolone, n (%) 4 (0.6) 2 (0.2) 7 (6.2) 0.407 
Pregnancy outcomes     
- PE, n (%) 8 (1.3) ** 34 (4.1) +++ 9 (8.0) ‡‡‡ <0.0001 
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Group 1 vs Group 2: *p<0.05, ** p<0.01, ***p<0.001; Group 2 vs Group 3: +p<0.05, ++p<0.01, +++p<0.001; Group 1 vs Group 3: ‡p<0.05, ‡‡p<0.01, 
‡‡‡
 p<0.001 
 
a = includes respiratory distress syndrome, need for ventilation, sepsis, necrotizing enterocolitis, neonatal hypoglycemia 
PE= preeclampsia; SGA = small for gestational age; CS = cesarean section 
The three groups were compared using the chi-square test or Fisher’s exact test for categorical variables. The Kruskal-Wallis test or the 
one-way ANOVA tests with post hoc analysis was used for not-normally and normally distributed data, respectively. 
 
 
- Preterm PE<37 weeks, n (%) 1 (0.2) ** 8 (1.0) +++ 2 (1.8) ‡ 0.001 
- Gestational hypertension, n (%) 15 (2.4) 40 (4.8) 5 (4.4) 0.050 
- Gestational diabetes, n (%) 27 (4.3) 40 (4.8) 7 (6.2) 0.654 
- Birth < 37 weeks gestation, n (%) 10 (1.6) ** 38 (4.6) 8 (7.1) ‡‡‡ 0.001 
- Gestational age at birth, median 
(IQR) 
39.7 
(39.0 to 40.7) * 
40.0  
(39.0 to 40.9) 
+++
39.0  
(38.2 to 40.1) ‡‡‡ 
<0.0001 
Neonatal outcomes     
- Birth-weight (g) 3483.3 (504.9) *** 3323.4 (551.5) ++ 3122.2 (591.5) ‡‡‡ <0.0001 
-  Birth-weight z-score 0.14 (1.02) *** -0.27 (1.09) + -0.55 (1.29) ‡‡‡ <0.0001 
-  Birth-weight percentile 57.6  
(29.2 to 80.5) *** 
40.4  
(17.7 to 69.3) 
28.5  
(8.5 to 61.2) ‡‡‡ 
<0.0001 
- Birth-weight <5th centile 31 (4.9) ** 74 (8.9) ++ 20 (17.7) ‡‡‡ <0.0001 
Perinatal Mortality 1 (0.2) 3 (0.3) 1 (0.9) 0.573 
Neonatal morbidity,a n (%) 18 (2.8) ** 49 (5.9) 4 (3.5) 0.017 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
29 
 
Table 2. Multilevel linear mixed-effects models for maternal hemodynamic variables: 
estimated marginal means with 95% confidence interval.  
 
 
 
 Visit 1 Visit 2 Visit 3 Visit 4 
Log10 Cardiac 
output  
    
Group 1 0.706 (0.678- 0.734) 
0.733 
 (0.706- 0.761) 
0.758 *** 
(0.730- 0.786) 
0.743 *** 
(0.715- 0.771) 
Group 2 0.700
+++
 
(0.672- 0.727) 
0.725++ 
(0.698- 0.752) 
0.730 
(0.703- 0.757) 
0.720 ++ 
(0.693- 0.747) 
Group 3 0.737
‡‡
 
(0.704- 0.770) 
0.758‡ 
(0.725- 0.790) 
0.736‡ 
(0.703- 0.768) 
0.687‡‡‡ 
(0.654- 0.720) 
Log10 Peripheral 
vascular 
resistance  
    
Group 1 3.225 (3.188- 3.262) 
3.181** 
(3.144- 3.217) 
3.154*** 
(3.117- 3.191) 
3.181*** 
(3.145- 3.218) 
Group 2 3.228
++
 
(3.192- 3.264) 
3.196+++ 
(3.160- 3.232) 
3.188 
(3.152- 3.224) 
3.210+ 
(3.173- 3.246) 
Group 3 3.194
‡‡
 
(3.154- 3.235) 
3.156‡ 
(3.116- 3.196) 
3.189‡‡ 
(3.148- 3.229) 
3.235‡‡‡ 
(3.194- 3.275) 
Log10 Stroke 
Volume     
Group 1 1.854 (1.811-1.898) 
1.868 
(1.824-1.911) 
1.870*** 
(1.826-1.913) 
1.853* 
(1.810-1.897) 
Group 2 1.854
++
 
(1.810-1.897) 
1.864 
(1.820-1.907) 
1.847 
(1.803-1.890) 
1.840++ 
(1.797-1.8830 
Group 3 1.889
‡‡
 
(1.841-1.936) 
1.882 
(1.835-1.929) 
1.848 
(1.801-1.896) 
1.807‡‡‡ 
(1.759-1.854) 
Heart Rate     
Group 1 82.679 (81.034-84.324) 
85.493 
(83.878-87.109) 
90.014 
(88.401-91.627) 
90.430*** 
(88.815-92.044) 
Group 2 81.712 (80.163-83.262) 
84.883 
(83.361-86.406) 
89.232 
(87.710-90.753) 
88.669 
(87.139-90.198) 
Group 3 82.476 (80.174-84.779) 
87.959 
(85.770-90.147) 
90.425 
(88.252-92.598) 
89.072 
(86.890-91.255) 
Log10 Mean 
arterial pressure  
    
Group 1 2.008 (1.991-2.024) 
1.991*** 
(1.975-2.007) 
1.988*** 
(1.972-2.004) 
2.000*** 
(1.984-2.016) 
Group 2 2.009 (1.993-2.024) 
2.001++ 
(1.985-2.017) 
1.998 
(1.982-2.014) 
2.010+ 
(1.994-2.026) 
Group 3 2.009 (1.992-2.025) 
1.995‡ 
(1.978-2.012) 
1.999‡‡ 
(1.983-2.016) 
2.000 
(1.983-2.017) 
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Figure legends 
Figure 1. Linear mixed-effects model with estimated marginal means and 95% 
confidence intervals for Log10 cardiac output and Log10 peripheral vascular resistance 
in parous women without previous preeclampsia or small for gestational age (black 
line) compared to nulliparous women (red line) to parous women with previous 
preeclampsia or small for gestational age (blue line). 
Figure 2. Linear mixed-effects model with estimated marginal means and 95% 
confidence intervals for Log10 stroke volume, heart rate and Log10 mean arterial 
pressure in parous women without previous preeclampsia or small for gestational 
age (black line) compared to nulliparous women (red line) and to parous women with 
previous preeclampsia or small for gestational age (blue line). 
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Supplementary results: Multilevel linear mixed-effects models  
The fixed and random effects of the best multilevel models are shown in 
Supplementary Table 1 and the estimated marginal means are shown in 
Table 2 and Figures 1 and 2. 
For Log10CO, A random intercept – random slope model provided a 
significantly better fit to the data than did the base model (LR =670, 
degrees of freedom = 20, P < 0.01) or a random intercept model (LR=12, 
degrees of freedom = 1, P < 0.01). 
For Log10SV, A random intercept – random slope model provided a 
significantly better fit to the data than did the base model (LR = 472, 
degrees of freedom = 20, P < 0.01) or a random intercept model (LR=12, 
degrees of freedom = 1, P < 0.01). 
For HR, A random intercept – random slope model provided a 
significantly better fit to the data than did the base model (LR = 1716, 
degrees of freedom = 21, P < 0.01) or a random intercept model (LR=6, 
degrees of freedom = 1, P < 0.025). 
For Log10PVR, A random intercept – random slope model provided a 
significantly better fit to the data than did the base model (LR = 558, 
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degrees of freedom = 21, P < 0.01) or a random intercept model (LR=10, 
degrees of freedom = 1, P =0.01).  
For Log10MAP, a random intercept model provided a significantly better 
fit to the data than did the base model (LR = 799, degrees of freedom = 
25, P < 0.01) or a random intercept – random slope model (LR=9, 
degrees of freedom = 1, P < 0.01). 
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Table S1. Multilevel linear mixed-effects models for maternal hemodynamic variables: fixed effects. 
A multilevel linear mixed-effects model was performed for the repeated measures analysis of the maternal hemodynamic variables. 
 
There was no significant contribution from smoking, chronic hypertension, asthma, preeclampsia and small for gestational age on Log10 
cardiac output and Log10 stroke volume. There was no significant contribution from age, Log10weight, smoking, asthma, prednisolone, 
preeclampsia and small for gestational age Log10 peripheral vascular resistance.    
 
Parameter Log10 Cardiac output Log10 Peripheral vascular resistance Log10 Stroke volume 
Fixed part Estimate Standard error p-value Estimate Standard error p-value Estimate Standard error p-value 
Intercept 0.227 0.045 < 0.0001 3.637 0.051 < 0.0001 1.052 0.050 < 0.0001 
Age (years) -0.002 0.0003 < 0.0001    -0.0008 0.0003 0.023 
Height (cm) 0.003 0.0002 < 0.0001 -0.003 0.0003 < 0.0001 0.004 0.0003 < 0.0001 
Weight (Kg) 0.0007 0.0001 < 0.0001    0.0003 0.0001 0.015 
Race (reference White)   < 0.0001   < 0.0001   < 0.0001 
Black -0.014 0.004 0.003 0.007 0.005 0.156 -0.027 0.005 < 0.0001 
South Asian 0.030 0.008 < 0.0001 0.025 0.009 0.005 -0.038 0.008 < 0.0001 
East Asian -0.047 0.011 < 0.0001 0.047 0.013 < 0.0001 -0.049 0.012 0.0001 
Mixed -0.013 0.010 0.189 0.0004 0.011 0.966 -0.010 0.011 0.370 
Smoking (reference non-smokers)          
Medical co-morbidities (reference no)          
Chronic Hypertension    0.035 0.015 0.02    
Asthma          
Autoimmune  -0.061 0.026 0.020 0.086 0.030 0.004    
Anti-hypertensives (reference no)          
Labetalol    0.048 0.009 < 0.0001    
Nifedipine/Methyldopa)    0.051 0.016 0.002    
Prednisolone (reference no)       0.088 0.0431 0.041 
Preeclampsia (reference yes)          
Small for gestational age (reference no)          
Groups (reference nulliparous)   < 0.0001   < 0.0001   0.036 
Multiparous, previous PE/SGA -0.032 0.010 0.002 0.024 0.011 0.0301 -0.033 0.011 0.002 
Multiparous, no previous PE/SGA 0.023 0.005 < 0.0001 -0.0281 0.005 < 0.0001 0.013 0.005 0.020 
Time (four visits)   < 0.0001   < 0.0001   < 0.0001 
Interaction Groups with time   < 0.0001   < 0.0001   < 0.0001 
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Table S2. Multilevel linear mixed-effects models for maternal hemodynamic variables: fixed effects. 
 
Heart rate 
 
Log10 Mean Arterial Pressure 
Fixed part Estimate Standard error p-value Fixed part Estimate Standard error p-value 
Intercept 139.338 5.164 < 0.0001 Intercept 1.878 0.003 < 0.0001 
Age (years) -0.368 0.036 < 0.0001 Age (years) 0.0003 0.0001 0.031 
Height (cm) -0.274 0.032 < 0.0001 Height (cm)    
Log10 Weight (Log10 Kg) 0.097 0.012 < 0.0001 Log10 Weight (Log10 Kg) 0.0007 0.000047 < 0.0001 
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There was no significant contribution from smoking, chronic hypertension, asthma, autoimmune, anti-hypertensives and prednisolone on heart 
rate. There was no significant contribution from height on Log10 mean arterial pressure. 
 
 
Race (reference White)   < 0.0001 Race (reference White)   0.013 
Black 2.762 0.557 < 0.0001 Black -0.006 0.002 0.003 
South Asian 1.442 0.922 0.118 South Asian -0.006 0.003 0.051 
East Asian 0.599 1.350 0.657 East Asian -0.004 0.005 0.413 
Mixed -0.962 1.177 0.413 Mixed -0.006 0.004 0.156 
Smoking (reference non-smokers)    Smoking (reference non-smokers) -0.008 0.003 0.009 
Medical co-morbidities (reference no)    Medical co-morbidities (reference no)    
Chronic Hypertension    Chronic Hypertension 0.031 0.006 < 0.0001 
Asthma    Asthma 0.018 0.006 0.002 
Autoimmune     Autoimmune  0.0243 0.011 0.037 
Anti-hypertensives (reference no)    Anti-hypertensives (reference no)    
Labetalol    Labetalol 0.024 0.004 < 0.0001 
Nifedipine/Methyldopa)    Nifedipine/Methyldopa) 0.020 0.006 0.003 
Prednisolone (reference no)    Prednisolone (reference no)    
Preeclampsia (reference no) -2.888 1.138 0.011 Preeclampsia (reference no) 0.012 0.0052 0.017 
Small for gestational age (reference no) -1.830 0.744 0.014 Small for gestational age (reference no) 0.007 0.002 0.013 
Group (reference nulliparous)   0.025 Group (reference nulliparous)   < 0.0001 
Multiparous, previous PE/SGA 0.403 0.970 0.677 Multiparous, previous PE/SGA -0.009 0.004 0.016 
Multiparous, no previous PE/SGA 1.761 0.503 < 0.0001 Multiparous, no previous PE/SGA -0.010 0.002 < 0.0001 
Time (four visits)   < 0.0001 Time (four visits)   < 0.0001 
Interaction Group with time   0.004 Interaction Group with time   < 0.0001 
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Table S3. Multilevel linear mixed-effects models for maternal hemodynamic variables: estimated 
marginal means with 95% confidence interval: antilog values  
 Visit 1 Visit 2 Visit 3 Visit 4 
Cardiac output  
(L/min) 
    
Group 1 5.081 
(4.764 - 5.420) 
5.407 
(5.081- 5.767) 
5.727*** 
(5.370-6.109) 
5.533*** 
(5.188- 5.902) 
Group 2 5.011+++ 
(4.698-5.333) 
5.308++ 
(4.988-5.649) 
5.370 
(5.046-5.714) 
5.248++ 
(4.931-5.584) 
Group 3 5.457‡‡ 
(5.058-5.888) 
5.727‡ 
(5.308-6.165) 
5.445‡ 
(5.046-5.861) 
4.864‡‡‡ 
(4.508-5.248) 
Peripheral vascular 
resistance 
(dyn·s·cm−5) 
    
Group 1 
1678.804 
(1541.7- 
1828.1) 
1517.05** 
(1393.157-
1648.162) 
1425.608*** 
(1309.182-
1552.387) 
1517.05*** 
(1396.368-
1651.962) 
Group 2 
1690.441++ 
(1555.966- 
1836.538) 
1570.363+++ 
(1445.44- 
1706.082) 
1541.7 
(1419.058- 
1674.943) 
1621.81+ 
(1489.361- 
1761.976) 
Group 3 
1563.148‡‡ 
(1425.608- 
1717.908) 
1432.188‡ 
(1306.171- 
1570.363) 
1545.254‡‡ 
(1406.048- 
1694.338) 
1717.908‡‡‡ 
(1563.148- 
1883.649) 
Stroke Volume 
(ml)     
Group 1 71.449 (64.714-79.067) 
73.790 
(66.680-81.470) 
74.131*** 
(66.988-81.846) 
71.285* 
(64.565-78.886) 
Group 2 71.449
++
 
(64.565-78.886) 
73.113 
(66.069-80.723) 
70.307 
(63.533-77.624) 
69.183++ 
(62.661-76.383) 
Group 3 77.446
‡‡
 
(69.342-86.297) 
76.207 
(68.391-84.918) 
70.469 
(63.241-78.704) 
64.120‡‡‡ 
(57.411-71.449) 
Heart Rate 
(bpm) 
    
Group 1 82.679 (81.034-84.324) 
85.493 
(83.878-87.109) 
90.014 
(88.401-91.627) 
90.430*** 
(88.815-92.044) 
Group 2 81.712 (80.163-83.262) 
84.883 
(83.361-86.406) 
89.232 
(87.710-90.753) 
88.669 
(87.139-90.198) 
Group 3 82.476 (80.174-84.779) 
87.959 
(85.770-90.147) 
90.425 
(88.252-92.598) 
89.072 
(86.890-91.255) 
Mean arterial 
pressure (mmHg)  
    
Group 1 101.859 (97.949-105.681) 
97.949*** 
(94.406-101.624) 
97.274*** 
(93.756-100.925) 
100*** 
(96.382-103.752) 
Group 2 102.093 (98.401-105.681) 
100.230++ 
(96.605-103.992) 
99.540 
(95.940-103.276) 
102.329+ 
(98.627-106.169) 
Group 3 102.093 (98.174-105.925) 
98.855‡ 
(95.060-102.801) 
99.770‡‡ 
(96.161-103.752) 
100 
(96.161-103.992) 
